The late-stage study on so-called GLP-1 diabetes treatments, which was initially set to begin in the fourth quarter this year, was delayed as production of the drug fell behind schedule, according to the drug maker.
In 2015, French pharmaceutical firm Sanofi obtained an exclusive worldwide license to develop and commercialize the treatment. Hanmi retained an exclusive option to co-commercialize the products in Korea and China.
Shares in Hanmi fell 2.2 percent, or 9,000 won (US$7.86) to trade at 400,000 won as of 10:40 a.m.
By Park Han-na (firstname.lastname@example.org)